These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19458359)

  • 1. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.
    Tamburini J; Green AS; Bardet V; Chapuis N; Park S; Willems L; Uzunov M; Ifrah N; Dreyfus F; Lacombe C; Mayeux P; Bouscary D
    Blood; 2009 Aug; 114(8):1618-27. PubMed ID: 19458359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.
    Altman JK; Sassano A; Kaur S; Glaser H; Kroczynska B; Redig AJ; Russo S; Barr S; Platanias LC
    Clin Cancer Res; 2011 Jul; 17(13):4378-88. PubMed ID: 21415215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.
    Prabhu S; Saadat D; Zhang M; Halbur L; Fruehauf JP; Ong ST
    Oncogene; 2007 Feb; 26(8):1188-200. PubMed ID: 16936779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Ni L; Koeffler HP; Yokoyama A
    Exp Hematol; 2010 Aug; 38(8):666-76. PubMed ID: 20382200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Gery S; Koeffler HP; Yokoyama A
    Int J Cancer; 2009 Oct; 125(7):1710-20. PubMed ID: 19507250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.
    Willems L; Chapuis N; Puissant A; Maciel TT; Green AS; Jacque N; Vignon C; Park S; Guichard S; Herault O; Fricot A; Hermine O; Moura IC; Auberger P; Ifrah N; Dreyfus F; Bonnet D; Lacombe C; Mayeux P; Bouscary D; Tamburini J
    Leukemia; 2012 Jun; 26(6):1195-202. PubMed ID: 22143671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting translation in acute myeloid leukemia: a new paradigm for therapy?
    Tamburini J; Green AS; Chapuis N; Bardet V; Lacombe C; Mayeux P; Bouscary D
    Cell Cycle; 2009 Dec; 8(23):3893-9. PubMed ID: 19934662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.
    Thoreen CC; Kang SA; Chang JW; Liu Q; Zhang J; Gao Y; Reichling LJ; Sim T; Sabatini DM; Gray NS
    J Biol Chem; 2009 Mar; 284(12):8023-32. PubMed ID: 19150980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
    Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
    Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
    Tamburini J; Chapuis N; Bardet V; Park S; Sujobert P; Willems L; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
    Blood; 2008 Jan; 111(1):379-82. PubMed ID: 17878402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antileukemic activity of rapamycin in acute myeloid leukemia.
    Récher C; Beyne-Rauzy O; Demur C; Chicanne G; Dos Santos C; Mas VM; Benzaquen D; Laurent G; Huguet F; Payrastre B
    Blood; 2005 Mar; 105(6):2527-34. PubMed ID: 15550488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity.
    Liu L; Luo Y; Chen L; Shen T; Xu B; Chen W; Zhou H; Han X; Huang S
    J Biol Chem; 2010 Dec; 285(49):38362-73. PubMed ID: 20937815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
    Mi W; Ye Q; Liu S; She QB
    Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
    Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
    Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relieving autophagy and 4EBP1 from rapamycin resistance.
    Nyfeler B; Bergman P; Triantafellow E; Wilson CJ; Zhu Y; Radetich B; Finan PM; Klionsky DJ; Murphy LO
    Mol Cell Biol; 2011 Jul; 31(14):2867-76. PubMed ID: 21576371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.
    Green AS; Chapuis N; Maciel TT; Willems L; Lambert M; Arnoult C; Boyer O; Bardet V; Park S; Foretz M; Viollet B; Ifrah N; Dreyfus F; Hermine O; Moura IC; Lacombe C; Mayeux P; Bouscary D; Tamburini J
    Blood; 2010 Nov; 116(20):4262-73. PubMed ID: 20668229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.
    Yellen P; Saqcena M; Salloum D; Feng J; Preda A; Xu L; Rodrik-Outmezguine V; Foster DA
    Cell Cycle; 2011 Nov; 10(22):3948-56. PubMed ID: 22071574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.
    Meng H; Jin Y; Liu H; You L; Yang C; Yang X; Qian W
    J Hematol Oncol; 2013 Feb; 6():18. PubMed ID: 23415012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
    Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
    Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
    Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
    J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.